Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

Newly diagnosed Type 1 diabetes patients needed little or no insulin after treatment with the drug, UB researchers report.

In the recent SOUL trial, the GLP-1 drug reduced the risk of MACE by 14% over 4 years. Next up: a possible obesity indication.

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, ...

The Company’s investigational small moleculeglucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide further reduced risk for stroke vs. empagliflozin as treatment for diabetes. Dulaglutide’s impact on ...

Adults with obesity lose more weight with semaglutide than with placebo (a sham medication). However, the risk of unwanted events is probably higher than with placebo after 24 months. Semaglutide ...

A drug most often prescribed for diabetes and obesity might soon be prescribed to curb one of the world’s hardest to quit ...

Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin. Treating newly ...

Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin. Those are the ...